(WMC) - A molecular test could help identify breast cancer patients with the lowest risk of dying from the disease.
Mamma print, which was approved in 2007, tests for a 70-gene signature that pinpoints an 'ultralow' risk tumor.
That means the cancer has almost no risk of spreading or recurring, even 20 years after a tumor is removed.
Researchers say these patients could possibly avoid aggressive treatments, like radiation after a lumpectomy.
This study was led by researchers at UC San Francisco and published in 'Jama Oncology.'